Avalo Therapeutics (AVTX) Non Operating Investment Income (2019 - 2020)
Avalo Therapeutics' (AVTX) quarterly Non Operating Investment Income came in at -$1.9 million in Q2 2020, down 126.44% on a QoQ basis from $7.1 million in Q1 2020.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Non Operating Investment Income (2019 - 2020) Analysis & Trends
Avalo Therapeutics (AVTX) has 2 years of Non Operating Investment Income data on file, last reported at -$1.9 million in Q2 2020.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$1.9 million in Q2 2020, while the trailing twelve-month figure through Mar 2021 was -$1.9 million (down 126.24% YoY) and the FY2020 annual result came in at $5.2 million, up 9556.6% from the prior year.
- Non Operating Investment Income retreated to -$1.9 million in Q2 2020, from $7.1 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $7.1 million in Q1 2020 to a low of -$1.9 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 838.90 Mn | 838.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | -1.87 Mn |
| Mar 31, 2020 | 7.08 Mn |
| Dec 31, 2019 | 53,932.00 |